0.87
0.00%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Epigenomics
Its shares trade on Frankfurt under the ticker ECX.F. It has been listed since 19 July 2004. In the fiscal year to 31 December 2023, it reported revenue of €339,200 and a net loss of €4.5m. At that date it held total assets of €12.8m.
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. The company is headquartered in Berlin, Berlin. The company went IPO on 2004-07-19. The company develops and commercializes blood-based diagnostic products across multiple cancer indications. The firm's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. The company also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The firm is present in Europe and the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Jul 2004
- Employees
- 37
- Website
- epigenomics.com ↗
Leadership
Pay as last reported
- Dr. Helge LubenowChairwoman of the Supervisory Board, since 2016€25,000
- Mr. Alexander LinkDeputy Chairman of the Supervisory Board, since 2020€25,000
- Mr. Hansjoerg PlaggemarsMember of the Management Board
- Mr. Jochen HummelMember of the Supervisory Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Epigenomics AG develops Epi proColon for colorectal cancer screening in Europe and the US.
- The company offers Epi proLung for lung cancer detection in blood plasma across multiple cancer indications.
- Epigenomics AG has 37 full-time employees focused on molecular diagnostics and IVD product development.
Weaknesses
- The company's IPO was on 19 July 2004, which is over 20 years ago.
- Epigenomics AG has a small workforce of 37 employees in the Health Care sector.
- The company's presence is limited to Europe and the United States with no other regions.
Opportunities
- Epigenomics AG can expand its blood-based diagnostic products to new cancer indications in Europe.
- The company may grow its market share in the US with Epi proLung for lung cancer detection.
- Epigenomics AG could leverage its IVD services for research and regulatory approval in new markets.
Threats
- The Health Care sector faces increasing regulatory challenges for blood-based cancer diagnostics.
- Epigenomics AG's small team of 37 employees may struggle with scaling operations.
- Competition in the Biotechnology industry is intensifying for cancer screening products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.